Accession NumberDB00038  (BTD00021, BIOD00021)
GroupsApproved, Investigational

Oprelvekin, the active ingredient in Neumega® is recombinant Interleukin eleven, which is produced in Escherichia coli (E. coli) by recombinant DNA technology. The protein has a molecular mass of approximately 19,000 daltons, and is non-glycosylated. The polypeptide is 177 amino acids in length (the natural IL-11 has 178). This alteration has not resulted in measurable differences in bioactivity either in vitro or in vivo.

The primary hematopoietic activity of Neumega® is stimulation of megakaryocytopoiesis and thrombopoiesis. In mice and nonhuman primate studies Neumega® has shown potent thrombopoietic activity in compromised hematopoiesis, including moderately to severely myelosuppressed animals. In these studies, Neumega® improved platelet nadirs and accelerated platelet recoveries compared to controls.

In animal studies Oprelvekin also has non-hematopoetic activities. This includes the regulation of intestinal epithelium growth (enhanced healing of gastrointestinal lesions), the inhibition of adipogenesis, the induction of acute phase protein synthesis (e.g., fibrinogen), and inhibition of macrophageal released pro-inflammatory cytokines.

Protein structureDb00038
Related Articles
Protein chemical formulaC854H1411N253O235S2
Protein average weight19047.2 Da
>DB00038 sequence
Download FASTA Format
Adipogenesis inhibitory factor
Interleukin-11 precursor
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NeumegaKitWyeth Bio Pharma Division Of Wyeth Pharmaceuticals Inc., A Subsidiary Of Pfizer Inc.1997-11-012017-04-30Us
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CAS number145941-26-0

Increases reduced platelet levels due to chemotherapy

Structured Indications

Oprelvekin is indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in adult patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia. The primary hematopoietic activity of Oprelvekin is stimulation of megakaryocytopoiesis and thrombopoiesis. Oprelvekin has shown potent thrombopoietic activity in individuals with compromised hematopoiesis

Mechanism of action

Oprelvekin binds to the interleukin 11 receptor which leads to a cascade of signal transduction events. IL-11 is a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production.

TargetKindPharmacological actionActionsOrganismUniProt ID
Interleukin-11 receptor subunit alphaProteinyes
HumanQ14626 details
Related Articles

Absolute bioavailability is over 80%.

Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of elimination

The kidney is the primary route of elimination. The amount of intact Neumega in urine was low, indicating that the molecule was metabolized before excretion.

Half life

6.9 +/- 1.7 hrs

ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Oprelvekin.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Oprelvekin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Oprelvekin.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Oprelvekin.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Oprelvekin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Oprelvekin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Oprelvekin.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Oprelvekin.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Oprelvekin.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Oprelvekin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Oprelvekin.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Oprelvekin.Approved, Investigational
Food InteractionsNot Available
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesL03AC02 — Oprelvekin
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (57.8 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
1, 2TerminatedTreatmentExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedPreventionVon Willebrand 's disease Type 11
2CompletedTreatmentChronic Myelogenous Leukemia (CML) / Chronic Myeloid Leukemia (CML) / Leukemias1
2CompletedTreatmentHemophilia A / Von Willebrand 's disease Type 11
2CompletedTreatmentVon Willebrand 's disease Type 11
2TerminatedPreventionVon Willebrand 's disease Type 11
2TerminatedTreatmentSevere Thrombocytopenia1
Not AvailableRecruitingNot AvailableHemostatic Disorders1
ManufacturersNot Available
Dosage forms
Unit descriptionCostUnit
Neumega 5 mg vial352.9USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Experimental Properties
hydrophobicity-0.070Not Available
isoelectric point11.16Not Available
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available


Pharmacological action
General Function:
Transmembrane signaling receptor activity
Specific Function:
Receptor for interleukin-11. The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells. Essential for the normal development of craniofacial bones and teeth. Restricts suture fusion and t...
Gene Name:
Uniprot ID:
Uniprot Name:
Interleukin-11 receptor subunit alpha
Molecular Weight:
45221.925 Da
  1. Nandurkar HH, Robb L, Begley CG: The role of IL-II in hematopoiesis as revealed by a targeted mutation of its receptor. Stem Cells. 1998;16 Suppl 2:53-65. [PubMed:11012177 ]
  2. Li R, Hartley L, Robb L: Cloning of rat interleukin 11 and interleukin 11 receptor alpha chain and analysis of their expression in rat uterus in the peri-implantation period. Reproduction. 2001 Oct;122(4):593-600. [PubMed:11570967 ]
  3. Nandurkar HH, Hilton DJ, Nathan P, Willson T, Nicola N, Begley CG: The human IL-11 receptor requires gp130 for signalling: demonstration by molecular cloning of the receptor. Oncogene. 1996 Feb 1;12(3):585-93. [PubMed:8637716 ]
  4. Romas E, Udagawa N, Zhou H, Tamura T, Saito M, Taga T, Hilton DJ, Suda T, Ng KW, Martin TJ: The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med. 1996 Jun 1;183(6):2581-91. [PubMed:8676079 ]
  5. Nandurkar HH, Robb L, Tarlinton D, Barnett L, Kontgen F, Begley CG: Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood. 1997 Sep 15;90(6):2148-59. [PubMed:9310465 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23